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Abstract
Background: Coronavirus disease 2019 (COVID-19) emerged as a worldwide health crisis, over-
whelming healthcare systems. Elevated cardiac troponin T (cTn T) at admission was associated with 
increased in-hospital mortality. However, data addressing the role of cTn T in major adverse cardiovas-
cular events (MACE) in COVID-19 are scarce. Therefore, we assessed the role of baseline cTn T and 
cTn T kinetics for MACE and in-hospital mortality prediction in COVID-19. 
Methods: Three hundred and ten patients were included prospectively. One hundred and eight patients 
were excluded due to incomplete records. Patients were divided into three groups according to cTn T 
kinetics: ascending, descending, and constant. The cTn T slope was defined as the ratio of the cTn T 
change over time. The primary and secondary endpoints were MACE and in-hospital mortality.
Results: Two hundred and two patients were included in the analysis (mean age 64.4 ± 16.7 years, 
119 [58.9%] males). Mean duration of hospitalization was 14.0 ± 12.3 days. Sixty (29.7%) patients had 
MACE, and 40 (19.8%) patients died. Baseline cTn T predicted both endpoints (p = 0.047, hazard ratio 
[HR] 1.805, 95% confidence interval [CI] 1.009–3.231; p = 0.009, HR 2.322, 95% CI 1.234–4.369). 
Increased cTn T slope predicted mortality (p = 0.041, HR 1.006, 95% CI 1.000–1.011). Constant 
cTn T was associated with lower MACE and mortality (p = 0.000, HR 3.080, 95% CI 1.914–4.954,  
p = 0.000, HR 2.851, 95% CI 1.828–4.447). 
Conclusions: The present study emphasizes the additional role of cTn T testing in COVID-19 patients 
for risk stratification and improved diagnostic pathway and management. (Cardiol J 2021; 28, 6: xx-xx)
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Coronavirus disease 2019 (COVID-19) 
emerged as a worldwide health crisis, overwhelm-
ing healthcare systems and especially the intensive 
care units, due to high numbers of critical cases 
in a short period of time [1, 2]. Initial publications 
reported elevated cardiac troponin T (cTn T) at 
admission to be associated with a worse progno-
sis and increased in-hospital mortality, possibly 
due to myocardial injury [3, 4]. However, most 
of these series evaluated one troponin assay and 
focused on non-cardiovascular adverse events, for 
example intensive care unit admissions, and the 
need for ventilation or vasopressor support [5–7]. 
Current data addresses insufficiently the associa-
tion between cTn T and adverse cardiovascular 
events in COVID-19 patients. By analogy with 
acute coronary syndromes, the change of cardiac 
biomarkers levels over time may indicate myocar-
dial injury [8–11], which may develop at any point 
during hospitalization. Thus, serial cTn T testing 
might play a key role in the assessment of disease 
severity [9]. Moreover, it has been suggested that 
constant values of cTn T during hospitalization con-
vey an improved prognosis in COVID-19 patients, 
whereas a continuous increase in cTn T values 
implies a worse outcome [9]. However, few data 
are available to support this hypothesis. 
Therefore, we aimed to assess the additional 
prognostic value of baseline cTn T and cTn T 
kinetics in the prediction of major adverse cardio-
vascular events (MACE) and in-hospital mortality 
in COVID-19 hospitalized patients. 
Methods 
We prospectively included 310 patients admit-
ted to the Universitair Ziekenhuis Brussel (Univer-
sity Hospital of Brussels), Belgium between March 
2020 and April 2020. COVID-19 was confirmed by 
real-time reverse transcription polymerase chain 
reaction test. One hundred and eight patients with 
incomplete information on comorbidities, treat-
ment history, lack of systematic evaluation of the 
clinical status or biomarkers, and/or short period 
of hospitalization (< 48 h in hospital stay) were ex-
cluded from the analysis. Clinical information was 
collected at admission and during hospitalization 
by the physicians in charge. Data included demo-
graphics, medical history, comorbidities, clinical 
evaluation, laboratory exams, in-hospital treat-
ment, complications, and outcomes. Two hundred 
and two (65.1%) patients had at least two cTn T 
values assessed during hospitalization, systemati-
cally at 24–48 hours intervals, after hospital admis-
sion. cTn T-values > 0.011 µg/L were considered 
elevated, according to hospital laboratory cut-offs. 
cTn T evolution was analyzed by calculating the 
slope of change as the ratio of the cTn T change 
and the change in time (DcTn T/D time). DcTn T 
was defined as the difference between the high-
est value of cTn T during hospitalization and the 
baseline value. Baseline cTn T was considered the 
first cTn T assessment in the first 48 hours after 
hospital admission.
Patients were divided into three groups accord-
ing to their cTnT kinetics profile, as follows: group 1 
representing ascending cTn T profile, formed by 
patients with a variation of cTn T values from ad-
mission to discharge, with increased slope (DcTn 
T/D time ≥ 1); group 2, descending cTn T profile in-
cluded patients with a decrease of cTn T values from 
admission to discharge (DTn T/D time < 1); and 
group 3, constant cTn T profile, included patients 
with a stable value of cTn T during hospitalization 
(DcTn T/D time = 0). MACE was considered as the 
primary endpoint, composed of all-cause mortal-
ity, acute heart failure, acute coronary syndrome, 
pericarditis, myocarditis, atrial fibrillation or flutter, 
and pulmonary embolism. In-hospital mortality was 
considered as the secondary endpoint. All cardio-
vascular events were defined according to current 
practice guidelines of cardio logy [11–15].
Ethical approval
This study was approved by the local Ethical 
Committee and was carried out in accordance with 
the ethical principles for medical research involving 
human subjects established by the Helsinki Dec-
laration, protecting the privacy of all participants, 
as well as the confidentiality of their personal 
information.
Statistical analyses
Descriptive statistics were performed for 
all study variables. Continuous variables were 
expressed as mean ± standard deviation (SD) or 
median (interquartile [IQR]) for skewed variables. 
Categorical variables were expressed as percent-
ages. Normality of data was tested using the Kol-
mogorov-Smirnov test. Comparison of continuous 
variables was performed using Student’s t-test or 
the Mann-Whitney U-test, and of binominal vari-
ables using the c2 or Fisher exact test, respectively. 
Comparison between three groups was performed 
using one-way ANOVA for continuous data. Uni-
variable and multivariable Cox regression models 
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were used to evaluate potential predictors of in-
hospital mortality and MACE. 
Kaplan-Meier survival curves were used to 
compare event-free and survival rates for COVID-19 
patients by the log-rank test. Receiver operating 
characteristics (ROC) curves were constructed to 
determine the ability of baseline cTn T to predict 
mortality and MACE and to identify its sensitivity 
and specificity.
Data were analyzed using IBM SPSS Statis-
tic for Windows, Version 26.0 (Armonk, NY: IBM 
Corp.). A p value < 0.05 was considered significant.
Results
Global population: Baseline characteristics 
Two hundred and two patients were included 
in the analysis (mean age 64.4 ± 16.7 years, 119 
[58.9%] males). The mean duration of hospitaliza-
tion was 14.0 ± 12.3 days.
The prevalence of cardiovascular risk factors 
was the following: hypertension in 102 (50.5%) 
patients, dyslipidemia in 83 (41.1%) patients, dia-
betes mellitus in 61 (30.2%) patients, and obesity 
in 56 (27.9%) patients. Chronic kidney disease was 
observed in 29 (14.4%) patients. 
Baseline characteristics of the global study 
population and the comparison between patients 
with and without primary and secondary endpoints 
are shown in Supplemental Material Table 1. 
Clinical outcomes of the main population 
Major adverse cardiovascular events occurred 
in 60 (29.7%) patients. Twenty-three (11.4%) pa-
tients developed acute heart failure, 5 (2.6%) pa-
tients developed acute coronary syndrome (1 acute 
myocardial infarction with ST segment elevation, 
2 patients with acute myocardial infarction without 
ST segment elevation and 2 Takotsubo syndrome), 
4 (2%) patients developed pericarditis, 4 (2%) 
developed myocarditis, and 3 (1.3%) developed 
pulmonary embolism. Fourteen (6.9%) patients 
had acute onset of atrial fibrillation, and 1 (0.5%) 
patient had atrial flutter.
The in-hospital mortality rate was 40 (19.8%) 
patients. 
Factors associated with MACE and in- 
-hospital mortality in the main population 
Baseline cTn T. Univariable and multivariable 
Cox regression analyses for MACE and in-hospital 
mortality are shown in Table 1. Baseline cTn T 
independently predicted MACE (p = 0.047, haz-
ard ratio [HR] 1.805, 95% confidence interval [CI] 
1.009–3.231) and in-hospital mortality (p = 0.009, 
HR 2.322, 95% CI 1.234–4.369).  
For MACE, sensitivity and specificity of base-
line cTn T (best cut-off value 0.014 µg/mL) were 
92.6% and 60.1%, respectively, with an area under 
the curve of 0.80 (95% CI 0.73–0.87) (Fig. 1A), 
and for in-hospital mortality: sensitivity 77.1% 
Table 1. Cox regression analysis for major adverse cardiovascular events (MACE) and for in-hospital 
mortality in COVID-19 patients for baseline cardiac troponin T (cTn T).
Parameter Univariable analysis Multivariable analysis
HR 95% CI P HR 95% CI P 
MACE predictors
Age 1.056 1.032–1.081 0.000 1.054 1.025–1.084 0.000
cTn T 1.966 1.225–3.154 0.005 1.805 1.009–3.231 0.047
Neutrophil-lymphocyte ratio 1.059 1.025–1.093 0.001 0.997 0.955–1.040 0.877
C-reactive protein 1.004 1.002–1.007 0.002 1.004 1.001–1.007 0.021
History of diabetes mellitus 1.232 0.689–2.201 0.482 1.238 0.276–5.551 0.780
History of arterial hypertension 1.502 0.864–2.614 0.150 0.889 0.428–1.847 0.752
History of dyslipidemia 1.194 0.689–2.071 0.527 0.894 0.202–3.968 0.883
In-hospital mortality
Age 1.069 1.040–1.098 0.000 1.061 1.029–1.094 0.000
Neutrophil-lymphocyte ratio 1.069 1.034–1.106 0.000 1.003 0.958–1.049 0.911
C-reactive protein 1.005 1.002–1.008 0.001 1.007 1.003–1.012 0.000
cTn T 2.138 1.338–3.416 0.001 2.322 1.234–4.369 0.009
History of diabetes mellitus 1.320 0.688–2.532 0.404 0.845 0.383–1.864 0.676
CI — confidence interval; HR — hazard ratio
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and specificity 78.8%; area under the curve 0.84 
(95% CI 0.77–0.90); and best cut-off value 0.029 
µg/mL (Fig. 1C). 
Kaplan-Meier survival analysis for MACE and 
in-hospital mortality showed significant differences 
between patients with a baseline cTn T more than 
0.014 µg/mL for MACE and more than 0.029 µg/mL 
for in-hospital mortality (X2 [2] = 24.0, p < 0.001, 
X2 [2] = 35.3, p < 0.001, respectively, Fig. 1B, D).
cTn T kinetics. Characteristics of groups 
according to cTn T kinetics are detailed in Sup-
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Figure 1. Receiver operating characteristics (ROC) and Kaplan-Meier analysis illustrating the role of baseline cardiac 
troponin T (cTn T) in major adverse cardiovascular events (MACE) and in-hospital mortality in COVID-19 patients. ROC 
analysis for baseline cTn T for predicting MACE (A) and in-hospital mortality (C). Kaplan-Meier survival curve analysis 
for MACE, Log Rank (Matel-Cox) value = 0.000 (B) and in-hospital mortality, Log Rank (Matel-Cox) value = 0.000 (D).
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Predictors of MACE and in-hospital mortality 
according to cTn T kinetics pattern
A constant cTn T profile was independently as-
sociated with lower MACE and in-hospital mortality 
rates comparing to the other two groups (p = 0.000, 
HR 3.080, 95% CI 1.914–4.954, p = 0.000; HR 
2.851, 95% CI 1.828–4.447, respectively). 
Conversely, a positive ascending slope was 
an independent predictor of in-hospital mortality 
(p = 0.041, HR 1.006, 95% CI 1.000–1.011).
The univariable and multivariable Cox regres-
sion analyses for MACE and in-hospital mortality 
are shown in Table 2.  
Kaplan-Meier survival analysis for MACE 
and in-hospital mortality, showed significant dif-
ferences between patients with a constant cTn T 
profile and other cTn T profiles, (X2 [2] = 43.4, 
p < 0.001, X2 [2] = 41.9, p < 0.001, respectively, 
Fig. 2A, B; 3). 
Discussion 
The main findings of this study were the fol-
lowing: 1) baseline cTn T independently predicted 
MACE and in-hospital mortality in COVID-19 
hospitalized patients; 2) a constant cTn T profile 
was independently associated with a lower risk 
of MACE and in-hospital mortality; and 3) a rapid 
increase of cTn T during hospitalization was associ-
ated with higher mortality rate but not with higher 
MACE rate in hospitalized COVID-19 patients.
The characteristics of our study population are 
similar to earlier reports [16]. Patients diagnosed 
with COVID-19 are older, implicitly more fragile, 
and have more cardiac risk factors, which pre-
dispose them to developing major cardiovascular 
events [17–19]. 
Previous studies primarily focused on the role 
of baseline cTn T in predicting non-cardiac major 
Table 2. Cox regression analysis for major adverse cardiovascular events (MACE) and for in-hospital 
mortality in COVID-19 patients with constant cardiac troponin T (cTn T) profile and Cox regression 
analysis for in-hospital mortality in COVID-19 patients with an ascending cTn T slope.
Parameter Univariable analysis Multivariable analysis
HR 95% CI P HR 95% CI P
MACE predictors in COVID-19 patients with constant cTn T profile 
Age 0.891 0.969–0.992 0.001 0.994 0.979–1.008 0.402
C-reactive protein 0.998 0.996–1.000 0.103 1.000 0.998–1.003 0.805
Neuthropil-lymphocyte ratio 0.964 0.933–0.997 0.035 1.011 0.969–1.054 0.615
Constant cTn T profile 3.133 2.140–4.589 0.000 3.080 1.914–4.954 0.000
History of diabetes mellitus 0.573 0.383–0.857 0.007 0.337 0.183–0.776 0.008
History of arterial hypertension 0.835 0.576–1.211 0.341 1.107 0.719–1.703 0.646
History of dyslipidemia 0.690 0.469–1.014 0.059 1.766 0.884–3.526 0.107
In-hospital mortality in COVID-19 patients with constant cTn T profile
Age 0.983 0.972–0.994 0.003 0.999 0.986–1.012 0.854
C-reactive protein 0.999 0.997–1.001 0.154 1.000 0.998–1.002 0.991
Neutrophil-lymphocyte ratio 0.967 0.937–0.999 0.041 1.006 0.968–1.045 0.769
Constant cTn T profile 3.076 2.131–4.440 0.000 2.851 1.828–4.447 0.000
History of diabetes mellitus 0.598 0.408–0.877 0.009 0.690 0.462–1.030 0.070
In-hospital mortality in COVID-19 patients with an ascending cTn T slope
Age 0.983 0.972–0.994 0.003 1.100 1.017–1.190 0.018
C-reactive protein 0.999 0.997–1.001 0.154 1.007 1.000–1.015 0.056
Neutrophil-lymphocyte ratio 0.967 0.937–0.999 0.041 1.045 0.957–1.142 0.327
Ascending slope 3.076 2.131–4.440 0.000 1.006 1.000–1.011 0.041
History of diabetes mellitus 0.598 0.408–0.877 0.009 0.629 0.141–2.811 0.544
CI — confidence interval; HR — hazard ratio
www.cardiologyjournal.org 5
Maria-Luiza Luchian et al., Troponin T in COVID-19: Kinetics matter
events such as intensive care unit admission, need 
for invasive ventilation or extracorporeal mem-
brane oxygenation, and in-hospital mortality [6, 7, 
10, 20]. Elevated cardiac biomarkers, especially 
cardiac troponin, were identified in about 10% to 
20% of hospitalized COVID-19 patients, especially 
Figure 3. Alluvial plot illustrating the distribution of values of baseline cardiac troponin T (cTn T) in COVID-19 patients 
divided into three kinetics profiles according on the values during hospitalization of cardiac troponin (ascending cTn T, 
descending cTn T, and constant cTn T) and the association with major cardiovascular events. First column: patients 
were divided into two groups based on the best cut-off value of baseline cTn T of 0.014 µg/mL (green: cTn T< 0.014 
µg/mL, purple: cTn T ≥ 0.014 µg/mL), which was shown as an independent predictor for major adverse cardiovascular 
events (MACE). Second column: patients were separated into three cTn T kinetics profiles: ascending troponin profile 
(orange), descending troponin profile (yellow), constant troponin profile (pink). Third column: Patients without MACE. 
Patients with MACE. 
0.00 0.00
0 010 1020 2030 3040 40
0.25 0.25
2X  [2] = 43.4, p < 0.001 2X  [2] = 41.9, p < 0.001
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Figure 2. Kaplan-Meier survival analysis on the role of constant troponin profile in major adverse cardiovascular 
events (MACE) and in-hospital mortality in COVID-19 patients. Kaplan-Meier survival curve analysis for MACE, Log 
Rank (Matel-Cox) value = 0.000 (A) and in-hospital mortality, Log Rank (Matel-Cox) value = 0.000 (B).
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in those with a more severe form of the disease 
and non-survivors [21]. Both cardiovascular comor-
bidities and high values of cTn T were correlated 
to higher morbidity and mortality in COVID-19 
patients [21]. However, the small number or even 
the complete absence of cTn T measurements at 
baseline and during hospitalization were among the 
most frequently encountered limitations of earlier 
reports. Thus, data on the cardiac involvement 
and potential mechanisms of myocardial injury in 
COVID-19 are still scarce.
Possible mechanisms attributed to myocar-
dial damage and previously observed in other 
viral infections such as influenza were: severe 
inflammation, oxygen mismatch supply-demand, 
thrombosis, and microvascular injury [6, 8, 22]. 
This is further supported by recent pathological 
reports on the presence of severe acute respira-
tory syndrome-coronavirus-2 in heart specimens, 
proving the cardiac tropism [23].
In the current study, elevated troponin levels 
at baseline were linked not only to higher mortality 
rates confirming the results of earlier reports [16], 
but they also independently predicted major cardio-
vascular events, with a high sensitivity and specific-
ity. These findings emphasize the susceptibility to 
myocardial injury related to COVID-19 infection. 
Sandoval et al. [9] postulated that in addition 
to baseline cTn T, stable concentrations of cTn T 
over time convey a lower risk of cardiovascular 
complications, such as myocarditis, pericarditis, 
or acute coronary syndromes, whereas a more 
in-depth approach is advised in patients with an 
increase in cTn T values in time. The present 
study reinforces this statement, by showing that 
a rapid increase of cTn T over a short period 
of time was independently associated with in-
hospital mortality. The increase in cTn T values 
may reflect the severity of myocardial injury and 
may be linked to the amplitude of inflammatory 
response [18, 21, 24]. 
In our cohort, higher values of C-reactive 
protein were associated with increased cTn T 
values during hospitalization. Moreover, baseline 
C-reactive protein was significantly associated 
with both major endpoints, suggesting that inflam-
mation acts as a trigger for acute cardiac damage 
and increases morbidity and mortality in these 
patients [25].
These findings are further supported by previ-
ous studies on severe acute respiratory syndrome 
(SARS) and Middle East respiratory syndrome 
(MERS), which showed that an exaggerated im-
mune response with release of inflammatory cy-
tokines may cause myocardial damage with high 
levels of cardiac biomarkers [26]. 
Interestingly, patients with constant troponin 
values during hospitalization had lower rates of 
death or major cardiovascular events, even though 
they might have had elevated baseline cTn T.
This finding suggests that the increase in cTn T 
at admission might be caused by extra cardiac 
factors, unrelated to cardiac events, supporting 
the additional role of serial cTn T testing in these 
patients [27, 28].  
Nevertheless, worse outcomes were also at-
tributed to COVID-19 patients with cardiovascular 
comorbidities and risk factors, such as arterial 
hypertension, obesity, or diabetes mellitus [5, 29]. 
However, in the present study, no significant differ-
ences in terms of cardiac risk factors or pathologies 
between cTn T groups according to cTn T kinetics 
were found, except for diabetes mellitus. Nonethe-
less, it was not linked to higher mortality or major 
cardiovascular events.
Hence, these results underline that the clini-
cal significance of serial testing in COVID-19 
patients should not be overlooked, irrespective of 
the presence of cardiovascular disease or risk fac-
tors. The findings of the present study emphasize 
the additional role of troponin testing, not only 
on admission, but also during hospitalization, for 
a better risk stratification and an improved diag-
nostic pathway. Moreover, patients with cardiac 
injury during hospitalization should be routinely 
monitored for mid- and long-term outcomes, fol-
lowing COVID-19 infection.
Limitations of the study
This study has several limitations. This is 
a single-center study with a limited number of 
patients. It might be argued that cardiac troponin 
was assessed in more severe forms of COVID-19. 
Due to logistical restriction at the beginning of the 
pandemic, some data regarding echocardiography, 
cardiac magnetic resonance, or systematic meas-
urements of cardiac biomarkers were lacking in 
some patients. Cardiovascular examinations were 
performed in selected cases based on the clinical 
and biological status of the patients, according to 
current guideline recommendations to avoid the 
risk of cross-infections [27, 30]. Therefore, serial 
echocardiographic evaluation was not available in 
all COVID-19 patients.
Nonetheless, patients who died were more 
likely to have missing data, including serial cardiac 
troponin testing. Thus, patients with incomplete 
data were excluded from the final analysis. 
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Also, in the present study less sensitive car-
diac troponin assays were used. However, the value 
of troponin in distinguishing patients with worse 
outcome was obvious. 
Multicenter research on a larger population 
with a standardized protocol is necessary to con-
firm our results.
Conclusions
Elevated cTn T at admission independently 
predicted MACE and in-hospital mortality in 
COVID-19 hospitalized patients. Moreover, a rapid 
increase in the value of cTn T was associated with 
higher mortality rates.  
Conversely, a constant cTn T profile was linked 
to lower rates of MACE and in-hospital mortality. 
These findings emphasize the additional value of 
serial troponin testing in COVID-19 patients, for 
risk stratification and improved diagnosis pathways 
and management.
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